Biomerica, Inc. announced that its Fortel Prostate Specific Antigen (PSA) Screening Test has received approval from the United Arab Emirates Ministry of Health and Prevention (MOHAP). This regulatory milestone allows Biomerica to introduce its innovative diagnostic tool into the UAE market. The Fortel PSA Screening Test is a user-friendly diagnostic that provides accurate results in just 10 minutes using a simple finger-prick blood sample.
The test measures elevated PSA levels, which are a recognized early marker of prostate disease, enabling early detection of prostate cancer and other prostate-related conditions. This rapid and accessible approach aims to enhance proactive health management and improve patient outcomes in the region. Prostate cancer is the second most common cancer among men worldwide, with 1.4 million new cases diagnosed globally in 2020.
This approval is part of Biomerica’s strategic initiative to expand its footprint in the Middle East, where prostate cancer is increasingly recognized as a critical public health concern. The company aims to replicate the success of its EZ Detect Colon Disease At-Home Screening Test, which previously received government insurance reimbursement in Dubai. Biomerica has established partnerships with leading distributors and secured key regulatory approvals to make early cancer detection more accessible.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.